Glossary
Immune-mediated necrotizing myopathy
The muscle blood test runs into the thousands here, which is what separates this from most muscle weakness. The antibody named on your report tells you less than everybody had assumed. That second part is the live argument in this corner of the field, and this page says so rather than hiding it.
What the research found.
One Australian study of 20 people found a median creatine kinase of 6047 units per liter, ranging from 1000 to 17000. Two or more immune treatments were needed in 90 percent of them. Four people reached complete remission, and the rest were still on treatment at the end of follow-up.
Ashton and colleagues, Journal of Clinical Neuroscience, 2016
One study of 133 people found no significant difference in overall outlook between the three antibody groups. Grouping them instead by what they had gave three types, one covering 56.4 percent with a better outlook and one covering 10.5 percent with the highest blood markers. The third covered 33.1 percent, with frequent lung disease and high mortality.
One 13-year study of 57 people compared the two antibody groups against each other. The anti-SRP group was younger at onset, at a median of 53 years against 66.5, at P under 0.001. It more often had lung disease, at 26.7 percent against 2.4 percent. Joint involvement reached 33.7 percent in that group against none at all in the other.
One study of 64 people found that lasting disability was common despite treatment coming from several directions at once. Moderate to severe disability affected 71 percent of the anti-HMGCR group. In the anti-SRP group it affected 60 percent of them.
What the name means
The name is long and every piece of it is doing work, so take it apart and it explains itself. Immune-mediated means your own immune system is driving the illness. Necrotizing means muscle fibers are being killed rather than only inflamed, and myopathy means a muscle disease.
So this is an immune attack that destroys muscle fibers directly, which is what sets it apart from the other kinds of muscle inflammation. In those the damage is more indirect. The difference sounds academic and it turns up plainly in the blood tests, which is the next section.
Why the blood test runs so high
Creatine kinase is an enzyme that lives inside muscle cells, and when those cells die it leaks out into the blood. That is what the test is measuring. Here the numbers are striking, and one Australian study of 20 people found a median creatine kinase of 6047 units per liter with a range from 1000 to 17000.
Those are high figures even among the muscle diseases, which is the reason for quoting them here. A very high creatine kinase points toward this diagnosis rather than another one. It's one of the first clues anybody gets, and more often than not it's what starts the search in earnest.
The three antibody groups
This illness gets sorted into three groups, and the third of them is the one people forget about. Anti-HMGCR is the first and anti-SRP is the second. Antibody-negative is the third, and it isn't a small group at all.
One study of 64 people found 17 with anti-HMGCR, 15 with anti-SRP, and 22 who were antibody-negative, with a further 9 who had incomplete testing. So the antibody-negative group was the largest single one in that study. A Chinese study of 117 people found a different split, where 36 were anti-SRP positive, 7 were anti-HMGCR positive, and 16 were antibody-negative.
What the antibody does and doesn't predict
This is the live argument in the field, and it's worth knowing that it's live rather than settled. Four of the sources gathered here arrange the illness by antibody, which is how it's usually described. One of them argues that doing so doesn't work.
That study followed 133 people and found no significant difference in overall outlook between the three antibody groups. It then grouped people by what they had rather than by what they tested for, and got three types instead. The first covered 56.4 percent and had muscle weakness with a better outlook.
The second covered 10.5 percent and had the highest creatine kinase and lactate dehydrogenase, with a middling outlook in the end. The third covered 33.1 percent, with a high rate of lung disease and a high death rate. The authors conclude that these antibodies don't sort patients well by lung risk or by outlook.
That's one study of 133 people set against four others that use the antibody framing. It's worth holding both of those in mind rather than picking one. Nobody in the field has settled this yet, and a page that pretended otherwise would be lying to you.
Where the antibody does seem to count
One study of 57 people ran over 13 years and found real differences between the two antibody groups. That held even though the overall outlook was similar between them. The anti-SRP group was younger at onset, at a median of 53 years against 66.5, at P under 0.001.
It more often had features outside the muscles as well. Lung disease appeared in 26.7 percent against 2.4 percent, and joint involvement appeared in 33.7 percent against none at all. Cancer turned up in 12.3 percent across both groups, and it was low in each of them separately too, which is a figure worth having because people ask.
In the anti-HMGCR group, the antibody level tracked with two other measures. It correlated with creatine kinase at 0.692, at P under 0.001, and with troponin T at 0.476, at P equals 0.014. Troponin T is a blood test of heart muscle rather than of skeletal muscle.
The antibody-negative group
Being antibody-negative isn't the mild form of this illness, whatever the name suggests. One Chinese study of 117 people describes how that group differs, and two of its findings stand out. Muscle pain at the start was more common there, at 62.5 percent against 23.3 percent, at P equals 0.0114.
Quiet heart involvement was more often found on heart scanning, at 7 of 7 tested against 12 of 24, at P equals 0.0261. Read that heart figure for what it is. Seven of seven is a striking proportion drawn from a very small number of people, so the direction is the useful part rather than the fraction.
One finding in that study went the other way. Deposition of a particular immune complex on the muscle fibers was less common in the antibody-negative group, at 16.7 percent against 68.2 percent. Marked improvement after immune treatment tended to be higher in that group, at 87.5 percent against 61 percent, though that didn't clear the usual threshold at P equals 0.0641.
The statin question
Some people with anti-HMGCR antibodies developed this illness after taking a statin, and that link is real. It's also more complicated than it first sounds. One study of 64 people looked at it, and of its 17 anti-HMGCR patients, 11 had taken a statin.
It compared those 11 against the anti-HMGCR patients who had never taken one at all. The ones who had never taken a statin did worse on three separate measures. They were more often men, at 67 percent against 45 percent, they more often needed third-line treatment, at 50 percent against 9 percent, and they more often had a poor or fatal outcome, at 50 percent against none.
So a statin history isn't the bad sign it might look like from the outside. Nothing on this page speaks to your own statin. That's a conversation with whoever prescribed it, it isn't a decision anybody should make from a page, and it isn't one that has to be made today.
How much people recover
Partly, for most people, and the figures are worth having rather than guessing at. Two studies give them. One study of 64 people measured lasting disability, where moderate to severe disability reached 71 percent in the anti-HMGCR group and 60 percent in the anti-SRP group, despite treatment coming from several directions.
One Australian study of 20 people gives the treatment side of the same question. Two or more immune treatments were needed in 90 percent of them, and eight people needed two particular treatments together. Four reached complete remission, and the rest were still on treatment at the end of follow-up.
Coming off treatment
Most people don't come off it, and reducing the treatment brings a problem of its own. Both halves of that are worth knowing before anybody starts. One 13-year study of 57 people measured treatment-free remission, which was reached by 21.4 percent of the anti-HMGCR group and by 13.0 percent of the anti-SRP group.
The Australian study states the mechanism behind that plainly enough. Weaning off steroids commonly brought relapses on. That's why reducing is done slowly, and it's why a plan to reduce is usually a plan rather than a stopping point somebody arrives at.
Common misconceptions.
Myth. My antibody tells me how this will go.
Reality. One study of 133 people set out to test that directly. It found no real difference in outlook between the three antibody groups, so it grouped people by their findings instead, and the three types that came out of that did differ. One of them had a high rate of lung disease and a high death rate, and the authors conclude these antibodies don't sort patients well by lung risk or outlook.
Myth. A negative antibody test means something milder.
Reality. Not on the evidence gathered here, and the numbers point the other way. One study of 64 people found 22 who were antibody-negative, which was its largest single group. One Chinese study of 117 people found antibody-negative patients had more muscle pain at the start, at 62.5 percent against 23.3 percent, and more quiet heart involvement on scanning, at 7 of 7 against 12 of 24.
Myth. If a statin caused it, stopping the statin fixes it.
Reality. Stopping is where treatment starts rather than where it ends. One study of 64 people compared two groups who shared the antibody, some of whom had taken a statin and some of whom never had. Those who never had did worse, needing third-line treatment more often, at 50 percent against 9 percent, and having a poor or fatal outcome more often, at 50 percent against none.
Myth. This is a mild kind of muscle inflammation.
Reality. The numbers say otherwise, and they say it plainly. One Australian study of 20 people found a median creatine kinase of 6047 units per liter, and two or more immune treatments were needed in 90 percent of them. Only four people reached full remission, and the rest were still on treatment at the end.
Myth. Once treatment works, it's finished.
Reality. Relapse on reducing treatment is a known problem rather than a rare surprise. One Australian study reports that weaning off steroids commonly brought relapses on. One 13-year study covered 57 people, where treatment-free remission was reached by 21.4 percent of the anti-HMGCR group and 13.0 percent of the anti-SRP group.
Related terms.
- Myositis, the wider group of muscle inflammation illnesses.
- Amyopathic dermatomyositis, the subtype where lungs matter most.
- Myositis blood tests, for what creatine kinase and the antibodies mean.
Questions patients ask.
What does the name mean?
Take the name in pieces and it explains itself. Immune-mediated means your own immune system drives it, necrotizing means muscle fibers are dying rather than only swelling, and myopathy means a muscle disease. So the whole name describes an immune attack that kills muscle fibers, which is what sets it apart from the other kinds of muscle inflammation.
Why is my creatine kinase so high?
Because muscle fibers are dying and that enzyme leaks out of them into the blood. One Australian study of 20 people found a median of 6047 units per liter, with a range running from 1000 to 17000. Those are high figures even among muscle diseases, and a very high result points toward this diagnosis rather than another.
What are the three antibody groups?
Anti-HMGCR, anti-SRP, and antibody-negative, which is the one people forget. One study of 64 people found 17 with anti-HMGCR, 15 with anti-SRP, and 22 who were antibody-negative. One Chinese study of 117 people found 36 with anti-SRP, 7 with anti-HMGCR, and 16 antibody-negative, so the proportions differ a great deal between places.
Does my antibody predict my outcome?
One study of 133 people says it predicts less than everybody had assumed. It found no real difference in outlook between the three groups, and grouping people by what they had gave three types instead, which did differ from each other. The authors conclude that these antibodies don't sort patients well by lung risk or by outlook.
What is the statin link?
Some people with anti-HMGCR antibodies developed this after taking a statin. One study of 64 people found 11 of its 17 anti-HMGCR patients had taken one, and those who never had did worse on three measures. Third-line treatment was needed by 50 percent against 9 percent, and a poor or fatal outcome came in 50 percent against none.
How well do people recover?
Partly, for most people, and the figures are worth having rather than guessing at. One study of 64 people measured lasting disability, which reached 71 percent in the anti-HMGCR group and 60 percent in the anti-SRP group, despite treatment from several directions. One Australian study of 20 people found only four reached full remission, with the rest still needing treatment.
Will I be able to stop treatment?
Some people do and most don't, on the evidence gathered here. One 13-year study covered 57 people, where treatment-free remission was reached by 21.4 percent of the anti-HMGCR group and 13.0 percent of the anti-SRP group. One Australian study notes that weaning off steroids commonly brought relapses, which is why reducing is done slowly.
Should my heart be checked?
It's worth asking about, though the numbers behind it are small. One Chinese study of 117 people looked for quiet heart involvement on scanning and found it in 7 of 7 antibody-negative patients tested, against 12 of 24 among the others. The P value was 0.0261, so read the direction of that rather than the fraction itself.
References.
- Ashton C; Junckerstorff R; Bundell C et al. Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective. Neuromuscul Disord. 2016;26:734-740. 10.1016/j.nmd.2016.08.013Retrospective series of 20 patients diagnosed with necrotising autoimmune myopathy at one Australian research institute between 2000 and 2015
- Wei X; Sun H; Pang Z et al. Novel phenotypes of immune-mediated necrotizing myopathy identified independent of myositis-specific antibody specificity that improve prognostic stratification. Front Immunol. 2026;17:1821033. 10.3389/fimmu.2026.1821033Retrospective study of 133 patients with immune-mediated necrotising myopathy
- Clark KEN; Clayton LM; Thomas RG et al. Clinical phenotypes and long-term outcomes of anti-SRP versus anti-HMGCR immune-mediated necrotising myopathy: a 13-year single-centre study. Clin Exp Rheumatol. 2026;44:247-254. 10.55563/clinexprheumatol/icqeffRetrospective observational comparative single-centre study of all 57 patients with anti-SRP or anti-HMGCR positive myopathy managed at a tertiary neuromuscular centre between 2010 and 2023: 15 anti-SRP and 42 anti-HMGCR
- Lim J; Rietveld A; De Bleecker JL et al. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurol Neuroimmunol Neuroinflamm. 2019;6:e513. 10.1212/NXI.0000000000000513Retrospective review of medical charts of 64 patients diagnosed with immune-mediated necrotising myopathy between 2012 and 2017 across three neuromuscular referral centres in the Netherlands and one in Belgium
- Ma X; Xu L; Ji S et al. The Clinicopathological Distinction Between Seropositive and Seronegative Immune-Mediated Necrotizing Myopathy in China. Front Neurol. 2021;12:670784. 10.3389/fneur.2021.670784Retrospective analysis of 117 patients with immune-mediated necrotising myopathy treated in one neurology department between January 2013 and December 2019
- Yang M; Yuan J; Wang Y et al. Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod. Front Immunol. 2024;15:1447182. 10.3389/fimmu.2024.1447182Open-label pilot observational study of seven patients with refractory immune-mediated necrotising myopathy
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.